Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer.
about
The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updatesMetabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinomaPancreatic cancer serum detection using a lectin/glyco-antibody array methodGemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response.Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer.A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancerIs plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancerMarkedly elevated CA19-9 associated with benign ovarian cyst and ascites.Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.The prognostic and predictive value of serum CA19.9 in pancreatic cancerCarbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution.Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.Is health screening beneficial for early detection and prognostic improvement in pancreatic cancer?Imaging of primary and metastatic pancreatic cancer using a fluorophore-conjugated anti-CA19-9 antibody for surgical navigation.Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis.Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma PathophysiologyUtility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal AdenocarcinomaPrognostic value of clinicopathological characteristics in patients with pancreatic cancerTrends in laboratory test volumes for Medicare Part B reimbursements, 2000-2010CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerCA 19-9 and pancreatic cancer.The Role of CA19-9 in Predicting Tumour Resectability in Carcinoma Head of PancreasCytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancerThe clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases.The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis.Diagnostic and prognostic biomarkers in pancreatic carcinoma.Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom ScoreCA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray.Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.Vaccine-induced antibody responses in patients with carcinoma.Current treatment options for pancreatic carcinoma.Molecular pathology of pancreatic cancer: from bench-to-bedside translation.Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3 Pancreatic Adenocarcinoma: Proposal for Reclassification of the Tumor Extending Beyond the Pancreas Based on Tumor Size.The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasLDevelopment and optimization of an antibody array method for potential cancer biomarker detection.
P2860
Q26865015-08084C2C-D88E-4FD7-A09B-2D2A550E3EDCQ28477463-E8EE0C9B-533C-4AE4-ACA1-A90BAF204889Q33391974-C7896433-9E18-495D-AF97-7CFCC77EB87CQ33443909-05552915-35DF-4695-8EEE-1B0B6C84839AQ33684453-190FFAF3-01AF-4C8D-983D-AEA8D3DAD2D1Q33728198-67E2BF85-7FDB-4799-A188-969C229A586FQ33796531-AB58355C-A54C-475F-90B1-6DD3C4678733Q34354775-76FDA31F-FB21-404D-B697-FCB5967A84C1Q34536365-CB253D5B-013E-4920-B505-1A81C0B9941DQ34635042-27035A69-2C39-4D91-B817-7FC4BC8912EDQ34635104-CB5FB5D3-7AB2-4CB7-A0F5-E0F545AD07D3Q34665177-86082CD0-D442-4F1D-9869-D18937A7C364Q35046670-7E12AB13-74D9-4E8C-877F-61483DF6E16DQ35057350-787BBCB8-E6DD-4553-AB59-2C023B66D80BQ35119157-C06A4F94-C015-472C-A62D-864BA35FF3BDQ35230680-C5E0CF02-DAF4-4673-AE80-B1DE9AD176D3Q35375731-C3611FE0-61BB-46D1-A676-40CB563BE4A2Q35903573-90FDAA6A-C49C-427F-B793-5AB666878AF3Q36025215-DECF43BD-5BFA-4D98-BE53-34FB837E70E5Q36134440-0AED63ED-68BB-40AB-AB27-134BE4D5C55EQ36227127-4874CC90-348A-478B-939F-8DB1A20BF4B7Q36423616-ACB0114F-9EE2-4E3F-9BA7-240E77DD82A0Q36716676-F4C12BDA-E0DC-435F-A95C-317F9024C866Q36786361-8F0361C9-E2F3-476D-8F4D-ABCDE344B7B2Q36831137-2ADE52D5-D835-45CB-89BC-B9DFC003E609Q36889709-95908A6A-3D3F-4B0C-9A00-C3952624C83DQ36937026-6593CC86-3399-4985-A174-82129261FE4CQ37054817-2E9990D9-0A95-4EF2-99DB-B77FE5D71854Q37284685-4CDDF02E-5C5E-4A87-989C-A4A987226734Q37350330-4C0B6340-EC7D-41E1-B089-256E13286A73Q37400577-46C93E95-0EFD-4934-AAF3-7F0B0EF5B2C2Q37479034-4543FAAF-01CD-469D-92B3-442EB0D5CA05Q37698104-414FEF8B-3C98-4197-8B5C-387427DBD382Q37762272-B2612E86-1E59-44FC-B3B5-DA56ECE0042CQ37864970-BB95B629-BB9F-480A-B478-4D04B1E90CFEQ37998096-9D18628B-98EB-48F9-B794-B090EDB665E0Q39148761-1B8FE819-47FA-4779-9A7D-375723267EEAQ40157678-63B71E58-952F-4B89-8D9E-F8650705EF7FQ41134742-008EEEB3-1763-40FB-A5FB-12DE69FD471BQ41162086-1063B652-F72E-47D9-B968-7D70DB3CB616
P2860
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Prognostic and therapeutic sig ...... tients with pancreatic cancer.
@ast
Prognostic and therapeutic sig ...... tients with pancreatic cancer.
@en
type
label
Prognostic and therapeutic sig ...... tients with pancreatic cancer.
@ast
Prognostic and therapeutic sig ...... tients with pancreatic cancer.
@en
prefLabel
Prognostic and therapeutic sig ...... tients with pancreatic cancer.
@ast
Prognostic and therapeutic sig ...... tients with pancreatic cancer.
@en
P2093
P2860
P356
P1433
P1476
Prognostic and therapeutic sig ...... tients with pancreatic cancer.
@en
P2093
Petra Stieber
Ralf Wilkowski
Stefan Boeck
Stefan Holdenrieder
Volker Heinemann
P2860
P304
P356
10.1159/000094888
P577
2006-08-04T00:00:00Z